Management of the neurological manifestations of APS - What do the trials tell us?

Thrombosis Research

Volumn 114, Issue 5-6 SPEC. ISS., 2004, Pages 489-499

  Brey, Robin L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Cerebrovascular disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; FLUINDOSTATIN; PHOSPHOLIPID ANTIBODY; SIMVASTATIN; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; BLEEDING; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; HUMAN; MEDICAL LITERATURE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; STROKE; SUBDURAL HEMATOMA; SYSTEMATIC REVIEW; THROMBOSIS; TIME SERIES ANALYSIS;

EID: 7044270690     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.06.018     Document Type: Article

References (42)

1. Wilson A., Gharavi A.E., Koike T. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum. 42:1999;1309-1311
2. Cervera R., Piette J.-C., Font J., Khamashta M.A., Shoenfeld Y., Camps M.T., et al. Antiphospholipid Syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum. 46:2002;1019-1027
3. Finazzi G., Brancaccio V., Moia M., Ciavarella N., Mazzucconi M.G., Schinco P.C., et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian registry. Am. J. Med. 100:1996;530-536
4. Brey R.L., Hart R.G., Sherman D.G., Tegeler C.H. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology. 40:1990;1190-1196
5. Levine S.R., Deegan M.J., Futrell N., Welch K.M.A. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology. 40:1990;1181-1189
6. Ginsburg K.S., Liang M.H., Newcomer L., Goldhaber S.Z., Schur P.H., Hennekens C.H., et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann. Intern. Med. 117:1992;997-1002
7. Nencini P., Baruffi M.C., Abbate R., Massai G., Amaducci L., Inzitari D. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke. 23:1992;189-193
8. APASS Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology. 43:1993;2069-2073
9. Muir K.W., Squire I.B., Alwan W., Lees K.R. Anticardiolipin antibodies in an unselected stroke population. Lancet. 344:1994;452-456
10. Levine S.R., Brey R.L., Sawaya K.L., Salowich-Palm L., Kokkinos J., Kostrzema B., et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann. Neurol. 38:1995;119-124
11. APASS Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology. 48:1997;91-94
12. Metz L.M., Edworthy S., Mydlarski R., Fritzler M.J. The frequency of phospholipid antibodies in an unselected stroke population. Can. J. Neurol. Sci. 25:1998;64-69
13. Toschi V., Motta A., Castelli C., Paracchini M.L., Zerbi D., Gibelli A. High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause. Stroke. 29:1998;1759-1764
14. Zielinska J., Ryglewicz D., Wierzchoska E., Lechowicz W., Hier D.B., Czlonkiwska A. Anticardiolipin antibodies are an independent risk factor for ischemic stroke. Neurol. Res. 21:1999;653-657
15. Tuhrim S., Rand J.H., Wu X., Horowitz D.R., Weinberger J., Goldman M.E., et al. Antiphosphatidylserine antibodies are independently associated with ischemic stroke. Neurology. 53:1999;1523-1527
16. Tuhrim S., Rand J.H., Wu X., Weinberger J., Horowitz D.R., Goldman M.E., et al. Elevated anticardiolipin antibody titer is an independent risk factor for stroke in a multiethnic population independent of istype or degree of positivity. Stroke. 30:1999;1561-1565
17. Tanne D., D_Olhaberriague L., Schultz L.R., Salowich-Palm L., Sawaya K.L., Levine S.R. Anticardiolipin antibodies and their associations with cerebrovascular risk factors. Neurology. 52:1999;1368-1373
18. Ahmed E., Stegmayr B., Trifunovic J., Weinehall L., Hallmans G., Lefvert A.K. Anticardiolipin antibodies are not an independent risk factor for stroke. An incident case-referent study nested within the MONICA and Vasterbotten cohort project. Stroke. 31:2000;1289-1293
19. Brey R.L., Abbott R.D., Curb J.D., Sharp D.S., Ross G.W., Stallworth C.L., et al. Beta(2) glycoprotein 1 dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke. 32:2001;1701-1706
20. Singh K., Gaiha M., Shome D.K., Gupta V.K., Anuradha S. The association of antiphospholipid antibodies with ischemic stroke and myocardial infarction in young and their correlation: a preliminary study. J. Assoc. Phys. India. 49:2001;529-537
21. Brey R.L., Stallworth C.L., McGlasson D.L., Wozniak M.A., Wityk R.J., Stern B.J., et al. Antiphospholipid antibodies and stroke in young women. Stroke. 33:2002;2396-2400
22. Blohorn A., Guegan-Massardier E., Triquenot A., Onnient Y., Tron F., Borg J.Y., et al. Antiphospholipid antibodies in the acute phase of cerebral ischemia in young adults: a descriptive study of 139 patients. Cerebrovasc. Dis. 13:2002;156-162
23. Tanne D., D'Olhaberriague L., Trivedi A.M., Salowich-Palm L., Schyltz L.R., Levine S.R. Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study. Neuroepidemiology. 21:2002;93-99
24. Cervera R., Khamashta M.A., Font J., Sebastiani G.D., Gil A., Lavilla P., et al. Morbidity and mortality in Systemic Lupus Erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine. 82:2003;299-308
25. Cervera R., Khamashta M.A., Font J., Sebastiani G.D., Gil A., Lavilla P., et al. Morbidity and mortality in Systemic Lupus Erythematosus during a 5-year period: a multicenter prospective study of 1000 patients. Medicine. 78:1999;167-175
26. APASS Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 291:2004;576-584
27. Sletnes K.E., Smith P., Abdolnoor M., Arnosen H., Wisloff F. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-heamorrhagic stroke. Lancet. 339:1992;451-453
28. Wu R., Nityanand S., Berlund L., Lithell H., Holm G., Lefvert A.K. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 17:1997;3159-3163
29. Rosove M.H., Brewer P.M.C. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann. Intern. Med. 117:1992;303-308
30. Khamashta M.A., Cuadrado M.J., Mujic F., Taub N.A., Hunt B.J., Hughes G.R.V. The management of thrombosis in the antiphospholipid antibody syndrome. NEJM. 332:1995;993-997
31. Crowther M.A., Ginsberg J.S., Julian J., Denburg J., Hirsch J., Douketis J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. NEJM. 349:2003;1133-1138
32. Ruiz-Ieastorza G., Khamashta K.A., Hunt B.J., Escuedero A., Cuadrado M.J., Hughes G.R.V. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: an analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch. Intern. Med. 162:2002;1164-1169
33. Derksen R.H.W.M., de Groot P.G., Kappelle L.J. Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. Neurology. 61:2003;111-114
34. Sanna G., Bertolaccini M.L., Cuadrado M.J., Khamashta M.A., Hughes G.R.V. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology. 42:2003;200-213
35. Cuadrado M.J., Lopez-Pedrera C., Khamashta M.A., Camps M.T., Tinahones F., Torres A., et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum. 40:1997;834-841
36. Meroni P.L., Raschi E., Testoni C., Tincani T., Balestrieri G., Molteni R., et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-β2-glycoprotein I) antibodies. Arthritis Rheum. 44:2001;2870-2878
37. Ferrara D.E., Liu X., Espinola R.G., Meroni P.L., Abukhalaf I., Harris E.N., et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum. 48:2003;3272-3279
38. Rapaport S.I., Rao L.V.M. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler. Thromb. 12:1992;1111-1121
39. Meroni P.L., Raschi E., Testoni C. Endothelium as a target for antiphospholipid antibodies and for therapeutical intervention. Autoimmun. Rev. 1:2002;55-60
40. Jacobsen E.M., Sandset P.M., Wisloff F. Do antiphospholipid antibodies interfere with tissue factor pathway inhibitor? Thromb. Res. 94:1999;213-230
41. Adams M.J., Donohoe S., Mackie I.J., Machin S.J. Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome. Br. J. Haematol. 114:2001;375-379
42. Pierangeli S.S., Gharavi A.E., Harris E.N. Experimental thrombosis and antiphospholipid antibodies: new insights. J. Autoimmun. 15:2000;241-247